Systemic administration of the potent H3 agonists, R-alpha-methylhistamine and immepip, had only minor sleep-promoting effects in the rat

Lamberty, Yves; Neveux, Michel; Margineanu, Doru Georg

doi:10.1016/s0924-977x(01)80504-6

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a separate study in cats, a 20 mg/kg oral dose increased deep slow wave sleep and decreased REM sleep [154]. By contrast, Monti et al [139] observed increases in SWS and decreases in waking and REM sleep in rats after intracerebral injection of R-methylhistamine, but not after intraperitoneal injection, a result corroborated in [155]. Species-specific effects in oral efficacy of these antagonists may be due to species-specific pharmacokinetic properties or to species-specific interactions of these agents with H 3 receptors.…”

Section: H 3 Agonists As Sleep-promoting Agentsmentioning

confidence: 86%

The Prevalence, Morbidities, and Treatments of Insomnia

Zammit

2007

CNSNDDT

View full text Add to dashboard Cite

Insomnia is a common condition that often is co-morbid with other illnesses. It is associated with significant morbidities, including nighttime distress, impaired cognitive functioning, impaired daytime functioning, and increased risk of accidents. People with insomnia utilize healthcare services more often than those without insomnia, and they are at greater risk for the development of certain health problems; most notably psychiatric illness such as depression. It is now known that the significant impact of insomnia warrants diagnosis and treatment. Behavioral and psychopharmacological treatments have been available for some time. However, formerly common classes of therapeutics such as the barbiturates and benzodiazepines have been replaced by new allosteric modulators of the GABA(A) receptor and other therapeutics with novel mechanisms of action. This article presents existing approaches to insomnia treatment, and reviews new treatments, therapeutic targets, and treatment approaches to insomnia under development that may offer promise to practitioners and patients.

show abstract

Section: H 3 Agonists As Sleep-promoting Agentsmentioning

confidence: 86%

The Prevalence, Morbidities, and Treatments of Insomnia

Zammit

2007

CNSNDDT

View full text Add to dashboard Cite

show abstract

Systemic administration of the potent H3 agonists, R-alpha-methylhistamine and immepip, had only minor sleep-promoting effects in the rat

Cited by 1 publication

References 0 publications

The Prevalence, Morbidities, and Treatments of Insomnia

The Prevalence, Morbidities, and Treatments of Insomnia

Contact Info

Product

Resources

About